Frankfurt Stock Exchange · Healthcare
Invest in BioNTech stock from India
Indian and foreign residents can buy BioNTech (22UA) shares directly through Paasa.
By Paasa · Updated
BioNTech at a glance
- Price
- €84.45+€2.05 (2.49%)
- Market cap
- €21.21B
- Day range
- €81.85 – €86.55
- P/E
- -12.51
- Dividend yield
- None
- Volume
- 21.00
- 1 month
- +0.78%
- 6 months
- +8.76%
- YTD
- +3.81%
- 1 year
- -7.40%
- 5 years
- -60.30%
BioNTech statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €2.8B | €2.8B | €3.8B | €17.3B | €19.0B |
| Gross profit | €2.1B | €2.2B | €3.2B | €12.8B | €15.1B |
| Operating income | −€624.1M | −€1.3B | €690.4M | €12.6B | €15.3B |
| Net income | −€1.1B | −€665.3M | €930.3M | €9.4B | €10.3B |
| Earnings per share | −€4.52 | −€2.77 | €3.87 | €38.08 | €43.87 |
| EBITDA | −€241.3M | −€367.1M | €1.4B | €12.9B | €15.7B |
| Total assets | €22.0B | €22.5B | €23.0B | €23.3B | €15.8B |
| Total debt | €267.4M | €254.2M | €219.1M | €212.2M | €301.5M |
| Cash and short-term investments | €14.8B | €16.8B | €16.5B | €14.1B | €2.1B |
| Shareholders' equity | €19.2B | €19.4B | €20.2B | €20.1B | €11.9B |
| Operating cash flow | €438.2M | €207.7M | €5.4B | €13.6B | €889.7M |
| Free cash flow | €269.9M | −€244.6M | €4.7B | €13.2B | €735.7M |
| Capital expenditure | −€168.3M | −€452.3M | −€705.5M | −€363.3M | −€154.0M |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Celltrion | 068270.KS | ₩179,600.00 | ₩41.19T |
| BeOne Medicines | 688235.SS | CNH 249.42 | CNH 260.83B |
| Innovent Biologics | 1801.HK | HK$92.65 | HK$161.30B |
| Sichuan Kelun-Biotech Biopharmaceutical | 6990.HK | HK$444.60 | HK$103.68B |
| Akeso | 9926.HK | HK$109.10 | HK$100.37B |
| Shanghai Junshi Biosciences | 688180.SS | CNH 33.83 | CNH 34.45B |
| Incyte | INCY | $112.79 | $22.86B |
| Genmab | GE9.F | €320.80 | €19.73B |
Peers as grouped by the data provider. This is not an investment recommendation.
Analyst price targets
- Low
- —
- High
- —
- Median
- —
- Consensus
- —
Ratings: 17 buy · 3 hold · 0 sell. Consensus: Buy.
Published sell-side 12-month targets in EUR, aggregated by the data provider. They are not Paasa's view and not a forecast.
How to invest in BioNTech from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search 22UA and buy
Find BioNTech by name or by its ticker, 22UA, and place your order.
Why invest in BioNTech from India
What BioNTech does
BioNTech SE is a biotechnology firm dedicated to the research, development, and marketing of immunotherapies for oncology and a spectrum of infectious diseases. Its diverse product pipeline features several FixVac candidates, including BNT111, currently undergoing Phase II clinical trials for advanced melanoma; BNT112, in Phase I/IIa development for prostate cancer; BNT113, progressing through Phase II for HPV-positive head and neck cancers; BNT114, in Phase I for triple-negative breast cancer; BNT115, also in Phase I for ovarian cancer; and BNT116, a preclinical asset targeting non-small c… BioNTech operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy BioNTech stock from India?
Yes. Indian residents and NRIs can buy BioNTech (22UA) shares directly through Paasa. BioNTech is listed on the Frankfurt Stock Exchange, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell BioNTech shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.